Corporate updates for Perspective Therapeutics (NYSE American: CATX) center on ongoing clinical developments, radiopharmaceutical pipeline trials, and regulatory milestones regarding its targeted alpha therapy programs for oncology care. The company routinely communicates progress through formal press releases and SEC filings detailing its research updates, clinical trial advancements, and financial burn rates.